Alnylam Pharmaceuticals, Inc. (ALNY) ownership: insiders 1% · institutions 100% (13F 2026-03-31). Insider activity, 90 days: Routine (10 sales, 0 open-market buys). 7 recent congressional STOCK Act disclosures. SEC EDGAR first-party data.
| Holder | Shares | Market Value | % Outstanding | Reported |
|---|---|---|---|---|
| Capital Group | 20387980.00 | $6.75B | 15.3% | 2026-03-31 |
| FMR (Fidelity) | 14579166.00 | $4.82B | 10.9% | 2026-03-31 |
| Vanguard | 13641524.00 | $4.51B | 10.2% | 2026-03-31 |
| BlackRock | 10444908.00 | $3.46B | 7.8% | 2026-03-31 |
| JPMorgan | 6323752.00 | $2.00B | 4.7% | 2026-03-31 |
| T. Rowe Price | 5193324.00 | $1.72B | 3.9% | 2026-03-31 |
| State Street | 3322698.00 | $1.10B | 2.5% | 2026-03-31 |
| Geode Capital Management | 2660385.00 | $884.57M | 2.0% | 2026-03-31 |
| Insider | Transaction | Value | Date |
|---|---|---|---|
| Sell | null | 2026-06-01 | |
| Sell | null | 2026-06-01 | |
| Sell | null | 2026-06-01 | |
| Sell | null | 2026-06-01 | |
| Sell | null | 2026-06-01 | |
| Sell | null | 2026-06-01 | |
| Sell | null | 2026-06-01 | |
| Sell | null | 2026-06-01 |
Back to ALNY overview · ALNY earnings · All congressional trades
Institutional data from SEC Form 13F. Insider data from SEC Form 4. Congressional data from STOCK Act disclosures. Not personalized investment advice.